Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | GMNN | O75496 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | MTOR | P42345 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2067263 | 0.73 | KDM4E (0.41) | KDM4DKDM4EPARP1CYP3A4CYP2D6 | |
| SCHEMBL342757 | 0.69 | PARP1 (0.44) | KDM4DKDM4EPARP1L3MBTL1SLC22A12 | |
| SCHEMBL4658815 | 0.66 | CYP2A6 (0.38) | KDM4DKDM4EPARP1CYP3A4CYP2D6 | |
| SCHEMBL18170736 | 0.66 | KDM4E (0.49) | KDM4EPARP1CYP3A4CYP2D6GMNN | |
| SCHEMBL4589677 | 0.57 | PARP1 (0.46) | KDM4EPARP1CYP3A4CYP2D6GMNN | |
| SCHEMBL29845529 | 0.57 | PARP1 (0.50) | KDM4EPARP1CYP3A4CYP2D6GMNN | |
| SCHEMBL256379 | 0.57 | PARP1 (0.50) | KDM4EPARP1CYP3A4CYP2D6GMNN | |
| SCHEMBL29865575 | 0.57 | PARP1 (0.55) | KDM4EPARP1CYP3A4CYP2D6GMNN | |
| SCHEMBL28822882 | 0.57 | PARP1 (0.55) | KDM4EPARP1CYP3A4CYP2D6GMNN | |
| SCHEMBL256383 | 0.56 | KDM4E (0.55) | KDM4DKDM4EPARP1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 598 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | DICERNA PHARMACEUTICALS, INC. (US) | 2023-07-11 | — | — | US | claimed |
| US-11359198-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-14 | — | — | US | claimed |
| US-20210292757-A1 | EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION | NOVO NORDISK A/S (DK) | 2021-09-23 | — | — | US | claimed |
| EP-3865576-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | Dicerna Pharmaceuticals, Inc. (US) | 2021-08-18 | — | — | EP | claimed |
| US-10870849-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2020-12-22 | — | — | US | claimed |
| US-10837013-B2 | Extended dicer substrate agents and methods for the specific inhibition of gene expression | DICERNA PHARMACEUTICALS, INC. (US) | 2020-11-17 | — | — | US | claimed |
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. | 2020-01-30 | — | — | US | claimed |
| EP-3234132-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | Dicerna Pharmaceuticals, Inc. (US) | 2017-10-25 | — | — | EP | claimed |
| WO-2016100401-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | DICERNA PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | claimed |
| US-20150038555-A1 | Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression | NOVO NORDISK A/S (DK) | 2015-02-05 | — | — | US | claimed |
| US-20150038554-A1 | Extended Dicer Substrate Agents and Methods for the Specific Inhibition of Gene Expression | NOVO NORDISK A/S (DK) | 2015-02-05 | — | — | US | claimed |
| US-20130041010-A1 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA CONTAINING MODIFIED NUCLEOTIDES | DICERNA PHARMACEUTICALS, INC. (US) | 2013-02-14 | — | — | US | claimed |
| US-20110288147-A1 | Compositions and methods for the specific inhibition of gene expression by DSRNA containing a tetraloop | DICERNA PHARMACEUTICALS, INC. | 2011-11-24 | — | — | US | claimed |
| EP-2341943-A2 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA POSSESSING MODIFICATIONS | Dicerna Pharmaceuticals, Inc. (US) | 2011-07-13 | — | — | EP | claimed |
| US-20100331389-A1 | Compositions and methods for the specific inhibition of gene expression by dsRNA containing modified nucleotides | DICERNA PHARMACEUTICALS, INC. | 2010-12-30 | — | — | US | claimed |
| WO-2010033225-A2 | COMPOSITIONS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DSRNA POSSESSING MODIFICATIONS | DICERNA PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | WO | claimed |
| EP-1828215-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | Alnylam Pharmaceuticals Inc. (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006093526-A2 | OLIGONUCLEOTIDES COMPRISING A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-09-08 | — | — | WO | claimed |
| US-20240229037-A1 | SIRNA TARGETING 17Beta-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE | TUOJIE BIOTECH (SHANGHAI) CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031862-A1 | LIGAND-MODIFIED DOUBLE-STRANDED NUCLEIC ACIDS | ADAR, NCL, SSU72 | KDM4D 4340/4885KDM4E 4665/4885PARP1 711/4885 |
| US-11697812-B2 | Methods and compositions for the specific inhibition of transthyretin (TTR) by double-stranded RNA | TTR, RNASE1, SARNP | KDM4D 4207/4885KDM4E 3806/4885PARP1 4093/4885 |
| US-20240229037-A1 | SIRNA TARGETING 17Beta-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE | HSD17B13, HSD17B1, HSD17B3 | KDM4D 3454/4885KDM4E 3439/4885PARP1 3467/4885 |
| US-20060035254-A1 | Oligonucleotides comprising a modified or non-natural nucleobase | NT5C3B, DERA, DUT | KDM4D 1430/4885KDM4E 2489/4885PARP1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.